Literature DB >> 6662110

Classification of phospholipases A2 according to sequence. Evolutionary and pharmacological implications.

M J Dufton, R C Hider.   

Abstract

The sequences of 32 phospholipases A2 (EC 3.1.1.4) were systematically compared on the basis of polypeptide chain length and similarity at selected amino acid positions around the active site. Two difference matrices were constructed and the various groupings present in the data were expressed in dendrogram form. The two methods of comparison yielded different results, and this is seen as a consequence of separate aspects of phospholipase evolution being highlighted in each case. It appears that, although Elapid snake venom phospholipases are very similar in terms of overall conformation, the area around their active sites distinguishes them into two major groups, namely the Asian Elapids and the marine/Australasian Elapids. Further, the Asian Elapids seem to have active-site vicinities which are closer to those in the mammalian pancreatic phospholipases. The relevance of the classifications to structure/activity relationships (especially beta-neurotoxicity) and phospholipase evolution is discussed.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6662110     DOI: 10.1111/j.1432-1033.1983.tb07860.x

Source DB:  PubMed          Journal:  Eur J Biochem        ISSN: 0014-2956


  13 in total

1.  Structural and phylogenetic basis for the classification of group III phospholipase A2.

Authors:  Gururao Hariprasad; Alagiri Srinivasan; Reema Singh
Journal:  J Mol Model       Date:  2013-06-23       Impact factor: 1.810

2.  The molecular cloning of a phospholipase A2 from Bothrops jararacussu snake venom: evolution of venom group II phospholipase A2's may imply gene duplications.

Authors:  A M Moura-da-Silva; M J Paine; M R Diniz; R D Theakston; J M Crampton
Journal:  J Mol Evol       Date:  1995-08       Impact factor: 2.395

3.  Epitope mapping of snake venom phospholipases A2 with pseudexin monoclonal antibodies.

Authors:  B G Stiles; J L Middlebrook
Journal:  J Protein Chem       Date:  1991-04

4.  Evolutionary relationships and implications for the regulation of phospholipase A2 from snake venom to human secreted forms.

Authors:  F F Davidson; E A Dennis
Journal:  J Mol Evol       Date:  1990-09       Impact factor: 2.395

5.  Modulation of human type II secretory phospholipase A2 by sphingomyelin and annexin VI.

Authors:  K Koumanov; C Wolf; G Béreziat
Journal:  Biochem J       Date:  1997-08-15       Impact factor: 3.857

6.  Interisland mutation of a novel phospholipase A2 from Trimeresurus flavoviridis venom and evolution of Crotalinae group II phospholipases A2.

Authors:  Takahito Chijiwa; Sachiko Hamai; Shoji Tsubouchi; Tomohisa Ogawa; Masanobu Deshimaru; Naoko Oda-Ueda; Shosaku Hattori; Hiroshi Kihara; Susumu Tsunasawa; Motonori Ohno
Journal:  J Mol Evol       Date:  2003-11       Impact factor: 2.395

7.  Molecular evolution of group II phospholipases A2.

Authors:  T Ogawa; M Kitajima; K Nakashima; Y Sakaki; M Ohno
Journal:  J Mol Evol       Date:  1995-12       Impact factor: 2.395

8.  Identification of the B subtype of gamma-phospholipase A2 inhibitor from Protobothrops flavoviridis serum and molecular evolution of snake serum phospholipase A2 inhibitors.

Authors:  Shuhei So; Takahito Chijiwa; Naoki Ikeda; Ikuo Nobuhisa; Naoko Oda-Ueda; Shosaku Hattori; Motonori Ohno
Journal:  J Mol Evol       Date:  2008-03-04       Impact factor: 2.395

9.  The finding of a group IIE phospholipase A2 gene in a specified segment of Protobothrops flavoviridis genome and its possible evolutionary relationship to group IIA phospholipase A2 genes.

Authors:  Kazuaki Yamaguchi; Takahito Chijiwa; Naoki Ikeda; Hiroki Shibata; Yasuyuki Fukumaki; Naoko Oda-Ueda; Shosaku Hattori; Motonori Ohno
Journal:  Toxins (Basel)       Date:  2014-12-18       Impact factor: 4.546

10.  Transcriptomic basis for an antiserum against Micrurus corallinus (coral snake) venom.

Authors:  Luciana I Leão; Paulo L Ho; Inacio de L M Junqueira-de-Azevedo
Journal:  BMC Genomics       Date:  2009-03-16       Impact factor: 3.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.